GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

Federal health officials upended the immunization schedule for American children this week. These are the diseases affected.

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

CDC recommendations have been altered for another vaccine, to the confusion of vaccination experts. The Observer has answers ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

The CDC's new vaccine schedule reduces recommended childhood vaccines from 17 to 11, impacting protection against diseases ...

The Centers for Disease Control and Prevention has scaled back routine childhood vaccine recommendations, shifting six widely ...

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...